Treatment
By: Maria Buti, MD, Anna S. F. Lok, MD, Patrick Marcellin, MD
|
Join Maria Buti, MD; Anna S. F. Lok, MD; and Patrick Marcellin, MD, as they review and discuss the latest data on the treatment of chronic HBV infection presented at the 2009 European Association for the Study of the Liver annual meeting.
Date Posted: 6/17/2009
|
By: Calvin Q. Pan, MD, FACP, FACG
|
Attempt this Interactive Case Challenge and learn strategies for frontline regimen selection and on-treatment management of patients with HBeAg-negative chronic HBV infection with Calvin Q. Pan, MD, FACP, FACG.
Date Posted: 6/9/2009
|
|
Daryl T-Y Lau, MD, MSc, MPH, and Wissam Bleibel, MD, discuss the advantages of tenofovir over adefovir for the treatment of chronic hepatitis B.
Date Posted: 6/4/2009
|
By: Robert G. Gish, MD
|
Robert G. Gish, MD, describes the latest data and reviews the most recent guidelines on the optimal selection of first-line therapy for patients with chronic hepatitis B infection.
Date Posted: 5/29/2009
|
 |
Download slide highlights from the CME-certified module on initial HBV therapies for self study and use in your own presentations.
File Format: Microsoft PowerPoint (.ppt) | File Size: 1.40 MB
Date Posted: 5/29/2009
|
By: Albert D. Min, MD
|
Learn about frontline regimen selection and on-treatment management of an HBeAg-positive patient and apply this learning with Albert D. Min, MD, in this Interactive Case Challenge.
Date Posted: 5/28/2009
|
 |
In 2 randomized trials, HBeAg-positive and HBeAg-negative patients receiving tenofovir for 48 weeks achieved higher rates of HBV DNA suppression vs adefovir and significantly more HBeAg-positive patients achieved ALT normalization and HBsAg loss with tenofovir vs adefovir.
File Format: Microsoft PowerPoint (.ppt) | File Size: 367 KB
Date Posted: 5/28/2009
|
 |
In a prospective study, > 0.5 log10 IU/mL decrease in HBsAg at Week 12 or > 1.0 log10 IU/mL decrease at Week 24 had high predictive value for subsequent SVR in HBeAg-negative patients treated with peginterferon alfa-2a.
File Format: Microsoft PowerPoint (.ppt) | File Size: 322 KB
Date Posted: 5/7/2009
|
|
Ira M. Jacobson, MD, discusses the predictive value of HBsAg decline in HBeAg-negative HBV-infected patients receiving peginterferon alfa-2a.
Date Posted: 5/6/2009
|
|
Baseline adefovir and lamivudine resistance mutations did not impair subsequent Week 96 response to tenofovir +/- emtricitabine.
Date Posted: 4/26/2009
|
|
Featured Content
Review the latest clinical data and best practices in the identified HCV mgmt target areas.
Review new data and Expert Highlights from the 2009 hepatitis meeting.
Learn the latest options for initiating HBV treatment through a text module, slides, and case challenges.
|
|